News

BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial

BenevolentAI, a leader in the application of AI and machine learning in drug discovery and development, announced dosing of the first patient in its randomised first-in-human clinical trial of BEN-2293, a molecule designed and developed by BenevolentAI to treat Atopic Dermatitis.

London, 11 February 2020 - This significant milestone sees a best in class, novel multi-target drug developed using BenevolentAI's scientific and technical expertise now entering human clinical trials.

BEN-2293 is a potent and selective small-molecule Pan-Trk antagonist formulated for topical delivery, with a pharmacokinetic profile designed for low systemic exposure to deliver the optimal safety and efficacy profile in the treatment of itch and inflammation associated with Atopic Dermatitis. In this initial trial, BEN-2293 will be studied in adult patients with mild to moderate disease.

Atopic Dermatitis is characterised as a chronic relapsing inflammatory skin condition which manifests as itchy, inflamed skin. The addressable global patient population is estimated at 230 million. Mild to moderate Atopic Dermatitis affects approximately 70% of all patients, with prevalence rising worldwide.

The current standard of care for the topical treatment of Atopic Dermatitis includes corticosteroids and calcineurin inhibitors which have limitations of use and adverse side effects. There remains a high unmet need for patients that are either non-responders or refractory to currently available treatments. BEN-2293 is positioned to address both the inflammation and itch associated with Atopic Dermatitis in both adults and children, representing a comprehensive, new treatment available for a broad patient population.

Anne Phelan, Chief Scientific Officer at BenevolentAI, commented, “The poor treatment options available for Atopic Dermatitis patients make the disease difficult to endure. It can impact the quality of life and psychosocial wellbeing, particularly among children, who make up around 10-20% of patients. New ways to treat this disease are desperately needed, and we believe our molecule has strong potential to address this serious unmet need without the use of topical steroids. The BEN-2293 trial also marks an important first step in the development of our in-house drug pipeline, and we are excited to be progressing this candidate into the clinic.”


Media enquiries

Rajin Kang

rajin.kang@benevolent.ai 

About BenevolentAI (www.benevolent.com)

BenevolentAI creates and applies AI and machine learning to transform the way medicines are discovered and developed. Benevolent integrates its technology into every step of the drug discovery process, from hypothesis generation to early-stage clinical development. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and offices in New York. BenevolentAI has active R&D drug programmes in disease areas such as ALS, Ulcerative Colitis, Atopic Dermatitis and Oncology and has research and commercial collaborations with AstraZeneca and Novartis.


More Posts

You Might Also Like

Blog
Transforming drug discovery with AI: how we’re building and nurturing the best talent for the job
At BenevolentAI, we are on a mission to bring life-changing medicines to patients, and we are looking for collaborative, mission-driven people to join our tech, drug discovery and business operations teams in London, Cambridge and New York.
Oct 17, 2021
News
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
Oct 14, 2021
Blog
Measuring bias: moving towards more inclusive health research outcomes #stateofai
Having shared our open-source Diversity Analysis Tool last year, we were tasked to investigate and demonstrate the lack of diversity in biomedical data as part of the State of AI Report 2021.
Oct 12, 2021
Blog
Expert-augmented computational drug discovery for rare diseases
Combining scientific expertise, computational tools and our AI-enhanced biomedical knowledge graph to successfully uncover a new drug combination for treating a rare brain cancer in children.
Sep 28, 2021
News
BenevolentAI appoints Dr John Orloff to its Board of Directors
Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.
Sep 9, 2021
Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021